Literature DB >> 28834170

Response to the letter entitled "Obstructive sleep apnea, excessive daytime sleepiness, and adherence to antihypertensive treatment: Questionnaire survey".

Camila Gosenheimer Righi1, Denis Martinez1,2, Sandro Cadaval Gonçalves1,2, Miguel Gus1,2, Leila Beltrami Moreira1,2, Sandra C Fuchs1, Flavio Danni Fuchs1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28834170      PMCID： PMC8031316          DOI： 10.1111/jch.13067

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  4 in total

1.  Risk for Obstructive Sleep Apnea by Berlin Questionnaire, but not daytime sleepiness, is associated with resistant hypertension: a case-control study.

Authors:  Miguel Gus; Sandro C Gonçalves; Denis Martinez; Erlon O de Abreu Silva; Leila B Moreira; Sandra C Fuchs; Flávio D Fuchs
Journal:  Am J Hypertens       Date:  2008-05-01       Impact factor: 2.689

2.  Obstructive sleep apnea and resistant hypertension: a case-control study.

Authors:  Sandro Cadaval Gonçalves; Denis Martinez; Miguel Gus; Erlon Oliveira de Abreu-Silva; Carolina Bertoluci; Isabela Dutra; Thais Branchi; Leila Beltrami Moreira; Sandra Costa Fuchs; Ana Cláudia Tonelli de Oliveira; Flávio Danni Fuchs
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

3.  Influence of high risk of obstructive sleep apnea on adherence to antihypertensive treatment in outpatients.

Authors:  Camila G Righi; Denis Martinez; Sandro C Gonçalves; Miguel Gus; Leila B Moreira; Sandra C Fuchs; Flavio D Fuchs
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-07       Impact factor: 3.738

4.  The influence of cognition, anxiety and psychiatric disorders over treatment adherence in uncontrolled hypertensive patients.

Authors:  Úrsula Jacobs; Mauro S De Castro; Flávio D Fuchs; Maria Beatriz C Ferreira
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.